Coronary artery disease risk factors in patients with schizophrenia: Effects of short term antipsychotic treatment

Journal of Psychopharmacology

Volumn 21, Issue 8, 2007, Pages 857-863

  Sarandol, Asli ^a   Kirli, Selcuk ^a   Akkaya, Cengiz ^a   Ocak, Nihal ^a   Eroz, Esma ^a   Sarandol, Emre ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Adiponectin; Antipsychotic; High sensitive C reactive protein; Homocysteine; Leptin; Lipoprotein oxidation; Paraoxonase; Schizophrenia; Tumour necrosis factor

Indexed keywords

ADIPONECTIN; AMISULPRIDE; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; ATYPICAL ANTIPSYCHOTIC AGENT; C REACTIVE PROTEIN; CLOZAPINE; COPPER SULFATE; HALOPERIDOL; HOMOCYSTEINE; LEPTIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANALYTIC METHOD; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; LIPID PEROXIDATION; MALE; NEPHELOMETRY; OXIDATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SPECTROPHOTOMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; ARYLDIALKYLPHOSPHATASE; C-REACTIVE PROTEIN; CARBOXYLIC ESTER HYDROLASES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LEPTIN; LIPOPROTEINS; MALE; MALONDIALDEHYDE; OXIDATION-REDUCTION; RISK FACTORS; SCHIZOPHRENIA; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35649003173     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107077609     Document Type: Article

References (56)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association, Washington, DC.
2. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez JM, Navarro MA, San L. (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65: 1335 - 1342
3. Atmaca M., Kuloglu M., Tezcan E., Ustundag B. (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64: 598 - 604
4. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. (1998) Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 101: 1581 - 1590
5. Baptista T., Beaulieu S. (2002) Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 47: 742 - 749
6. Belo L., Caslake M., Gaffney D., Santos-Silva A., Pereira-Leite L., Quintanilha A., Rebelo I. (2002) Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis 162: 425 - 432
7. Beltowski J. (2005) Protein homocysteinylation: a new mechanism of atherogenesis? Postepy Hig Med Dosw 59: 392 - 404
8. Beltowski J. (2006) Leptin and atherosclerosis. Atherosclerosis 189: 47 - 60.
9. Buege J.A., Aust S.D. (1978) Microsomal lipid peroxidation. Methods Enzymol 52: 302 - 310
10. Cao H., Girard-Globa A., Berthezene F., Moulin P. (1999) Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R polymorphism. J Lipid Res 40: 133 - 139
11. Cohn T.A., Remington G., Zipursky R.B., Azad A., Connolly P., Wolever T M S (2006) Insulin resistance and adiponectin levels in drug, free patients with schizophrenia: A preliminary report. Can J Psychiatry 51: 382 - 386
12. Clarke R. and Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015 - 2022
13. Curkendall S.M., Jingping M., Glasser D.B., Rose-Stang M., Jones J.K. (2004) Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Br J Psychiatry 65: 715 - 720
14. Eckerson H.W., Wyte M.C., La Du B.N. (1983) The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35: 1126 - 1138 Feingold K.R., Menon R.A., Moser A.H., Grunfeld C. (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139: 307 - 315
15. Friedewald W.T., Levy R.I., Fredrickson D.S. (1972) Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499 - 508
16. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. (1991) Purification of human serum paraoxonase/arylesterase: Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19: 100 - 106
17. Haagen L., Brock A. (1992) A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 30: 391 - 395
18. Hennekens C.H., Hennekens A.R., Hollar D., Casey D.E. (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150: 1115 - 1121
19. Herran A., Garcia-Unzueta M.T., Amado J.A., de La Maza M.T., Alvarez C., Vazquez-Barquero J.L. (2001) Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 179: 59 - 62
20. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., Kanai A., Kase A., Uchikado H., Hirayasu Y. (2006) Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20: 75 - 79
21. Huang T.L., Chen J.F. (2005) Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 80: 55 - 59
22. Jakubowski H. (2000) Calcium-dependent human serum homocysteine thiolactone hydrolyse: a protective mechanism against protein N-homocysteinylation. J Biol Chem 275: 3957 - 3962
23. Jarvik G.P., Rozek L.S., Brophy V.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., Furlog C.E. (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 Genotype. Arterioscler Thromb Vasc Biol 20: 2441 - 2447
24. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. (1998) Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97: 1029 - 1036
25. Jow G.M., Yang T.T., Chen C.L. (2006) Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord 90: 21 - 27
26. Kerkeni M., Addad F., Chauffert M., Chuniaud L., Miled A., Trivin F., Maaroufi K. (2006) Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 39: 821 - 825
27. Kivircik B.B., Alptekin K., Caliskan S., Comlekci A., Oruk G., Tumuklu M., Kurklu K., Arkar H., Turk A., Caliskan M., Yesil S. (2003) Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 795 - 799
28. Levine J., Sela B.A., Osher Y., Belmaker R.H. (2005) High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 29: 1181 - 1191
29. Levine J., Stahl Z., Sela B.A., Gavendo S., Ruderman V., Belmaker R.H. (2002) Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159: 1790 - 1792
30. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., Mackness M. (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107: 2775 - 2779
31. Mackness B., Davies G K., Turkie W., Lee E., Roberts D H., Hill E., Roberts C., Durrington P N., Mackness M I. (2001) Paraoxonase status in coronary hesrt disease: Are activity and concentration more important than genotype? Arterioscler Thromb vasc Biol 21: 1451 - 1457
32. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. (1993) Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 104: 129 - 135
33. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N. (1991) Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 86: 193 - 199
34. Matsumoto C., Ohmori O., Hori H., Shinkai T., Nakamura J. (2002) Analysis of association between the Gln192Arg polymorphism of the paraoxonase gene and schizophrenia in humans. Neurosci Lett 321: 165 - 168
35. Matsuzawa Y. (2006) Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Cardiovascular Medicine nat Clin Pract Cardiovasc Med 3: 35 - 42
36. McCreadie R.G. (2003) Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183: 534 - 539
37. Melkersson K., Dahl M.L. (2004) Adverse metabolic effects associated with atypical antipsychotics: Literature revew and clinical implications. Drugs 64: 701 - 723
38. Mosca L., Rubenfire M., Tarshis T., Tsai A., Pearson T. (1997) Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol 80: 825 - 830
39. Monteleone P., Fabrazzo M., Tortorella A., Maj M. (1997) Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71: 11 - 17
40. Muntjewerff J.W., Kahn R.S., Blom H.J., den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11: 143 - 149
41. Naudin J., Capo C., Giusano B., Mege J.L., Azorin JM (1997) A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 26: 227 - 233
42. Newcomer J.W., Haupt D.W. (2006) The metabolic effects of antipsychotic medications. Can J Psychiatry 51: 480 - 491
43. PischonGirman C.J., Hotamisligil G.S., Rifai N., Hu F B., Rimm E.B. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730 - 1737
44. Pischon T., Rimm E.B. (2006) Adiponectin: a promising marker for cardiovascular disease. Clin Chem 52: 797 - 799
45. Rashid S., Watanabe T., Sakaue T., Lewis G.F. (2003) Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity Clin Biochem 36: 421 - 429
46. Reif A., Pfuhlmann B., Lesch K.P. (2005) Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry 29: 1162 - 1168
47. Rifai N., Ridker P.M. (2001) High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem 47: 403 - 411
48. Ross R. (1999) Atherosclerosis is an inflammatory disease. N Engl J Med 340: 115 - 126
49. Sporn A.L., Bobb A.J., Gogtay N., Stevens H., Greenstein D.K., Clasen L.S., Tossell J.W., Nugent T., Gochman P.A., Sharp W.S., Mattai A., Lenane M.C., Yanovski J.A., Rapoport J.L. (2005) Hormonal correlates of clozapine-induced weight gain in psychotic children. An exploratory study. J Am Acad Child Adolesc Psychiatry 44: 925 - 933
50. Susser E., Brown A.S., Klonowski E., Allen R.H., Lindenbaum J. (1998) Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 44: 141 - 143
51. Sytherland W H.F., Walker R.J., de Jong S.A., van Rij A.M., Phillips V., Walker H.L. (1999) Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 19: 1340 - 1347
52. Varga Z., Paragh G., Seres I., Kakuk G., Karanyi Z., Karpati I., Matyus J., Csongradi E., Juhasz A., Balla J., Bajnok L. (2006) Hyperleptinemia is not responsible for decreased paraoxonase activity in hemodialysis patients. Nephron Clin Pract 103: 114 - 120
53. Tribble D.L., Holl L.G., Wood P.D., Krauss R.M. (1992) Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93: 189 - 199
54. Virgos C., Martorell L., Simo J.M. et al. (1999) Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. NeuroReport 10: 2035 - 2038
55. Witzum J.L. (1994) The oxidation hypothesis of atherosclerosis. Lancet 344: 793 - 795
56. Zhang A., Vertommen J., Van Gaal L, De Leeuw I. (1993) A rapid and simple method for measuring the susceptibility of low-density lipoprotein and very-low-density lipoprotein to copper-catalyzed oxidation. Clin Chim Acta 227: 159 - 173